Novacek G, Dejaco C, Knoflach P, Moschen A, Petritsch W, Vogelsang H, Reinisch W
Medizinische Universität Wien, Universitätsklinik für Innere Medizin III, Klinische Abteilung für Gastroenterologie und Hepatologie, Wien, Österreich.
Klinikum Wels, 1. Interne Abteilung, Wels, Österreich.
Z Gastroenterol. 2014 Feb;52(2):204-11. doi: 10.1055/s-0033-1355818. Epub 2014 Jan 31.
TNF alpha antibodies have clearly improved the outcome of moderately to severely active ulcerative colitis. Adalimumab is the first fully human, monoclonal TNF alpha antibody, which is administered subcutaneously. Since April 2012 adalimumab is approved for the treatment of moderately to severely active ulcerative colitis in patients who have not responded despite a full and adequate course of therapy with a corticosteroid and an immunosuppressant or who are intolerant to or have medical contraindications for such therapies. Adalimumab can induce and maintain clinical remission and mucosal healing compared to placebo in moderately to severely active ulcerative colitis, can reduce the rate of ulcerative colitis related hospitalisations and improve health-related quality of life. The response can be observed after two weeks of treatment. The safety profile of adalimumab is comparable to those of other TNF alpha inhibitors. Studies on the treatment of ulcerative colitis with adalimumab did not reveal new safety aspects. The present consensus report by the Working Group Inflammatory Bowel Diseases of the Austrian Society of Gastroenterology and Hepatology presents the existing evidence of adalimumab for the treatment of ulcerative colitis and is aimed to assist as code of its practice.
肿瘤坏死因子α（TNFα）抗体显著改善了中度至重度活动性溃疡性结肠炎的治疗效果。阿达木单抗是首个完全人源化的单克隆TNFα抗体，通过皮下注射给药。自2012年4月起，阿达木单抗被批准用于治疗中度至重度活动性溃疡性结肠炎，这些患者尽管接受了皮质类固醇和免疫抑制剂的充分完整疗程治疗仍无反应，或对这些疗法不耐受或存在医学禁忌。与安慰剂相比，阿达木单抗在中度至重度活动性溃疡性结肠炎中可诱导并维持临床缓解和黏膜愈合，可降低溃疡性结肠炎相关的住院率，并改善健康相关生活质量。治疗两周后即可观察到疗效。阿达木单抗的安全性与其他TNFα抑制剂相当。关于阿达木单抗治疗溃疡性结肠炎的研究未发现新的安全问题。奥地利胃肠病学和肝病学会炎症性肠病工作组的这份共识报告展示了阿达木单抗治疗溃疡性结肠炎的现有证据，旨在作为其实践指南提供帮助。
